Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study
Authors' conclusion
Our results provide a reassuring profile of effectiveness when switching from ADA originator to one of its biosimilars and between two different biosimilars.
Study context
- Population
- Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with ADA bio-originator or ABP501 ADA biosimilar who switched to SB5; followed up for 4 months
- Participants
- 110 vs 40
- Exposure
- Switch from ADA bio-originator to SB5 biosimilar and from ABP501 ADA biosimilar to SB5 biosimilar, before vs after switch
- ADA bio-originator to SB5n = 110
- ABP501 to SB5n = 40
- Outcome
- Remission/low disease activity, ADA bio-originator to SB5
- Follow-up
- 4 months (T4)
Methodological detailsmonocentric, non-medical switch
- Monocentric
- Non-medical switch
Main finding
As reported in the abstract
RR for moderate-high disease activity
2.6
95% CI 1.2–5.7
P = 0.01
By group
Observational data: associations, not effects.
Further findings
DAS28-CRP, DAPSA, ASDAS-CRP and BASDAI, ADA bio-originator to SB5 · 4 months
- No differences found
Patient global assessment-VAS, ADA bio-originator to SB5 (RA and PsA subgroups) · 4 months
- Worsening in RA
- P = 0.04
- Worsening in PsA
- P = 0.02
HAQ, ADA bio-originator to SB5 (PsA subgroup) · 4 months
- Worsening in PsA
- P = 0.03
DAS28-CRP, DAPSA, remission/low disease activity and patient-reported outcomes (PROs), ABP501 to SB5 · 4 months
- No differences compared to baseline
Original publication
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol. Published 21 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →